Previous studies in solid tumors have demonstrated that prolonged interferon signaling allows tumors to acquire STAT1-related epigenomic/genomic changes contributing to the maintenance of resistance to immune checkpoint blockades [76], with a major contributor of IFNG being tumor-associated T cells. The gene discussed is IFNG; the disease is neoplasm.